News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Roche Avastin Misses Endpoint in Pancreatic Cancer Study
November 13, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Nov 13 (Reuters) - Roche on Tuesday said a late-stage study of its cancer drug Avastin in combination with gemcitabine chemotherapy and Tarceva for pancreatic cancer did not meet the primary endpoint for survival.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Roche
MORE ON THIS TOPIC
Neuroscience
Epilepsy Biotech Nabs up to $570M in Deal With Italy’s Angelini Plus $140M Fundraising
May 27, 2025
·
1 min read
·
Annalee Armstrong
Gene therapy
Rocket’s Danon Disease Gene Therapy on Hold After Patient Death
May 27, 2025
·
2 min read
·
Tristan Manalac
Funding
Karuna, Naurex Alumni Launch New Biotech
to Modulate Synaptic Plasticity for Neuro Diseases
May 27, 2025
·
3 min read
·
Heather McKenzie
Rare diseases
Prothena Looks at Business Options as Phase III AL Amyloidosis Trial Fails
May 27, 2025
·
2 min read
·
Tristan Manalac
